TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Recruiting

Phase 1

TMLI & AlemtuzumabTMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Sponsor:

City of Hope Medical Center

Code:

NCT05384756

Conditions

Sickle Cell Disease

Eligibility Criteria

Sex: All

Age: 12 - 40

Healthy Volunteers: Accepted

Interventions

Alemtuzumab

Hematopoietic Cell Transplantation

Intensity-Modulated Radiation Therapy

Sirolimus

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by City of Hope Medical Center on 2024-12-31.